skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 362  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Market watch: Top drugs and companies by sales in 2017
Material Type:
Article
Add to My Research

Market watch: Top drugs and companies by sales in 2017

Nature reviews. Drug discovery, 2018-04, Vol.17 (4), p.232-232 [Peer Reviewed Journal]

COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2018 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2018.42 ;PMID: 29588516

Full text available

2
Antibiotic Resistance — Problems, Progress, and Prospects
Material Type:
Article
Add to My Research

Antibiotic Resistance — Problems, Progress, and Prospects

The New England journal of medicine, 2014-11, Vol.371 (19), p.1761-1763 [Peer Reviewed Journal]

Copyright © 2014 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMp1408040 ;PMID: 25271470

Full text available

3
Contribution of NIH funding to new drug approvals 2010–2016
Material Type:
Article
Add to My Research

Contribution of NIH funding to new drug approvals 2010–2016

Proceedings of the National Academy of Sciences - PNAS, 2018-03, Vol.115 (10), p.2329-2334 [Peer Reviewed Journal]

Volumes 1–89 and 106–114, copyright as a collective work only; author(s) retains copyright to individual articles ;Copyright © 2018 the Author(s). Published by PNAS. ;Copyright National Academy of Sciences Mar 6, 2018 ;Copyright © 2018 the Author(s). Published by PNAS. 2018 ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.1715368115 ;PMID: 29440428

Full text available

4
The $2.6 Billion Pill — Methodologic and Policy Considerations
Material Type:
Article
Add to My Research

The $2.6 Billion Pill — Methodologic and Policy Considerations

The New England journal of medicine, 2015-05, Vol.372 (20), p.1877-1879 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMp1500848 ;PMID: 25970049

Full text available

5
New uses for old drugs
Material Type:
Article
Add to My Research

New uses for old drugs

Nature (London), 2007-08, Vol.448 (7154), p.645-646 [Peer Reviewed Journal]

COPYRIGHT 2007 Nature Publishing Group ;COPYRIGHT 2007 Nature Publishing Group ;Copyright Nature Publishing Group Aug 9, 2007 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/448645a ;PMID: 17687303 ;CODEN: NATUAS

Full text available

6
The antibiotic paradox: why companies can't afford to create life-saving drugs
Material Type:
Article
Add to My Research

The antibiotic paradox: why companies can't afford to create life-saving drugs

Nature (London), 2020-08, Vol.584 (7821), p.338-341 [Peer Reviewed Journal]

COPYRIGHT 2020 Nature Publishing Group ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/d41586-020-02418-x ;PMID: 32814891

Full text available

7
An urgent call to raise the bar in oncology
Material Type:
Article
Add to My Research

An urgent call to raise the bar in oncology

British journal of cancer, 2021-11, Vol.125 (11), p.1477-1485 [Peer Reviewed Journal]

2021. The Author(s). ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-021-01495-7 ;PMID: 34400802

Full text available

8
Potential Life‐Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada
Material Type:
Article
Add to My Research

Potential Life‐Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada

The oncologist (Dayton, Ohio), 2020-01, Vol.25 (1), p.e130-e137 [Peer Reviewed Journal]

AlphaMed Press 2019 ;AlphaMed Press 2019. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2019-0314 ;PMID: 31506392

Full text available

9
Theranostic radiopharmaceuticals: established agents in current use
Material Type:
Article
Add to My Research

Theranostic radiopharmaceuticals: established agents in current use

British journal of radiology, 2018-11, Vol.91 (1091), p.20170969-20170969 [Peer Reviewed Journal]

2018 The Authors. Published by the British Institute of Radiology 2018 The Authors ;ISSN: 0007-1285 ;EISSN: 1748-880X ;DOI: 10.1259/bjr.20170969 ;PMID: 29474096

Full text available

10
Economics of New Oncology Drug Development
Material Type:
Article
Add to My Research

Economics of New Oncology Drug Development

Journal of clinical oncology, 2007-01, Vol.25 (2), p.209-216 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2006.09.0803 ;PMID: 17210942

Full text available

11
Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag
Material Type:
Article
Add to My Research

Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag

Circulation (New York, N.Y.), 2021-06, Vol.143 (25), p.2494-2496 [Peer Reviewed Journal]

ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.121.055463 ;PMID: 34152800

Full text available

12
How drugs are developed and approved by the FDA: current process and future directions
Material Type:
Article
Add to My Research

How drugs are developed and approved by the FDA: current process and future directions

The American journal of gastroenterology, 2014-05, Vol.109 (5), p.620-623 [Peer Reviewed Journal]

Copyright Nature Publishing Group May 2014 ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.1038/ajg.2013.407 ;PMID: 24796999

Full text available

13
Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
Material Type:
Article
Add to My Research

Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies

The New England journal of medicine, 2012-06, Vol.366 (24), p.2284-2293 [Peer Reviewed Journal]

Copyright © 2012 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;Copyright © 2012 Massachusetts Medical Society. 2012 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMsa1200223 ;PMID: 22591257 ;CODEN: NEJMAG

Full text available

14
FDA new drug approvals in Q3 2020
Material Type:
Article
Add to My Research

FDA new drug approvals in Q3 2020

Nature reviews. Drug discovery, 2020-11, Vol.19 (11), p.746-746 [Peer Reviewed Journal]

COPYRIGHT 2020 Nature Publishing Group ;Nature 2020. ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/d41573-020-00182-1 ;PMID: 33046853

Full text available

15
Drug Safety Sciences and the Bottleneck in Drug Development
Material Type:
Article
Add to My Research

Drug Safety Sciences and the Bottleneck in Drug Development

Clinical pharmacology and therapeutics, 2011-06, Vol.89 (6), p.788-790 [Peer Reviewed Journal]

2011 American Society for Clinical Pharmacology and Therapeutics ;ISSN: 0009-9236 ;EISSN: 1532-6535 ;DOI: 10.1038/clpt.2011.63 ;PMID: 21593756

Full text available

16
Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology
Material Type:
Article
Add to My Research

Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology

European heart journal, 2016-03, Vol.37 (9), p.747-754 [Peer Reviewed Journal]

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehv213 ;PMID: 26077039

Full text available

17
Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
Material Type:
Article
Add to My Research

Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage

PLoS medicine, 2017-01, Vol.14 (1), p.e1002190-e1002190 [Peer Reviewed Journal]

COPYRIGHT 2017 Public Library of Science ;COPYRIGHT 2017 Public Library of Science ;2017 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Kesselheim AS, Treasure CL, Joffe S (2017) Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. PLoS Med 14(1): e1002190. doi:10.1371/journal.pmed.1002190 ;2017 Kesselheim et al 2017 Kesselheim et al ;2017 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Kesselheim AS, Treasure CL, Joffe S (2017) Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. PLoS Med 14(1): e1002190. doi:10.1371/journal.pmed.1002190 ;ISSN: 1549-1676 ;ISSN: 1549-1277 ;EISSN: 1549-1676 ;DOI: 10.1371/journal.pmed.1002190 ;PMID: 28045970

Full text available

18
Speed, Safety, and Industry Funding — From PDUFA I to PDUFA VI
Material Type:
Article
Add to My Research

Speed, Safety, and Industry Funding — From PDUFA I to PDUFA VI

The New England journal of medicine, 2017-12, Vol.377 (23), p.2278-2286 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMhle1710706 ;PMID: 29211663

Full text available

19
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
Material Type:
Article
Add to My Research

Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers

Nature reviews. Drug discovery, 2010-04, Vol.9 (4), p.277-291 [Peer Reviewed Journal]

COPYRIGHT 2010 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2010 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd3079 ;PMID: 20186141

Full text available

20
The current challenges for vaccine development
Material Type:
Article
Add to My Research

The current challenges for vaccine development

Journal of medical microbiology, 2012-07, Vol.61 (Pt 7), p.889 [Peer Reviewed Journal]

EISSN: 1473-5644 ;DOI: 10.1099/jmm.0.039180-0 ;PMID: 22322337

Full text available

Results 1 - 20 of 362  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (324)

Refine My Results

Creation Date 

From To
  1. Before 1997  (14)
  2. 1997 To 2002  (40)
  3. 2003 To 2008  (108)
  4. 2009 To 2015  (145)
  5. After 2015  (57)
  6. More options open sub menu

Resource Type 

  1. Articles  (343)
  2. magazinearticle  (17)
  3. Books  (2)
  4. More options open sub menu

Language 

  1. English  (341)
  2. Japanese  (23)
  3. German  (8)
  4. French  (5)
  5. Spanish  (4)
  6. Norwegian  (3)
  7. Portuguese  (2)
  8. Swedish  (2)
  9. More options open sub menu

Searching Remote Databases, Please Wait